Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019

Importance: The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019) provided systematic estimates of incidence, morbidity, and mortality to inform local and international efforts toward reducing cancer burden.

Objective: To estimate cancer burden and trends globally for 204 countries and territories and by Sociodemographic Index (SDI) quintiles from 2010 to 2019.

Evidence Review: The GBD 2019 estimation methods were used to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALYs) in 2019 and over the past decade. Estimates are also provided by quintiles of the SDI, a composite measure of educational attainment, income per capita, and total fertility rate for those younger than 25 years. Estimates include 95% uncertainty intervals (UIs).

Findings: In 2019, there were an estimated 23.6 million (95% UI, 22.2-24.9 million) new cancer cases (17.2 million when excluding nonmelanoma skin cancer) and 10.0 million (95% UI, 9.36-10.6 million) cancer deaths globally, with an estimated 250 million (235-264 million) DALYs due to cancer. Since 2010, these represented a 26.3% (95% UI, 20.3%-32.3%) increase in new cases, a 20.9% (95% UI, 14.2%-27.6%) increase in deaths, and a 16.0% (95% UI, 9.3%-22.8%) increase in DALYs. Among 22 groups of diseases and injuries in the GBD 2019 study, cancer was second only to cardiovascular diseases for the number of deaths, years of life lost, and DALYs globally in 2019. Cancer burden differed across SDI quintiles. The proportion of years lived with disability that contributed to DALYs increased with SDI, ranging from 1.4% (1.1%-1.8%) in the low SDI quintile to 5.7% (4.2%-7.1%) in the high SDI quintile. While the high SDI quintile had the highest number of new cases in 2019, the middle SDI quintile had the highest number of cancer deaths and DALYs. From 2010 to 2019, the largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles.

Conclusions And Relevance: The results of this systematic analysis suggest that the global burden of cancer is substantial and growing, with burden differing by SDI. These results provide comprehensive and comparable estimates that can potentially inform efforts toward equitable cancer control around the world.

Citing Articles

Surgical management of metastatic lesions in the proximal femur: a systematic review.

Iljazi A, Andersen M, Brorson S, Petersen M, Sorensen M EFORT Open Rev. 2025; 10(2):104-114.

PMID: 40071964 PMC: 11825154. DOI: 10.1530/EOR-24-0138.

Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable....

Kodama Y, Ueshima K, Moriguchi M, Inaba Y, Yamashita T, Iwamoto H BMC Cancer. 2025; 25(1):434.

PMID: 40069616 PMC: 11895279. DOI: 10.1186/s12885-025-13648-5.

Exploring the experiences of cancer patients: What drives them to seek treatment outside their residential area and what are the experiences resulting from that decision? A qualitative study.

Pyo J, Lee M, Lee H, Ock M PLoS One. 2025; 20(3):e0319650.

PMID: 40063639 PMC: 11892868. DOI: 10.1371/journal.pone.0319650.

5-Hydroxymethylcytosine modifications in circulating cell-free DNA: frontiers of cancer detection, monitoring, and prognostic evaluation.

Song D, Zhang Z, Zheng J, Zhang W, Cai J Biomark Res. 2025; 13(1):39.

PMID: 40055844 PMC: 11887266. DOI: 10.1186/s40364-025-00751-9.

Disease burden of lung cancer attributable to metabolic and behavioral risks in China and globally from 1990 to 2021.

Li L, Zhang X, Jiang A, Guo X, Li G, Zhang M BMC Public Health. 2025; 25(1):911.

PMID: 40055772 PMC: 11887075. DOI: 10.1186/s12889-025-21941-y.

References

. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1250-1284. PMC: 7562819. DOI: 10.1016/S0140-6736(20)30750-9. View

Sharpless N . COVID-19 and cancer. Science. 2020; 368(6497):1290. DOI: 10.1126/science.abd3377. View

Foreman K, Lozano R, Lopez A, Murray C . Modeling causes of death: an integrated approach using CODEm. Popul Health Metr. 2012; 10:1. PMC: 3315398. DOI: 10.1186/1478-7954-10-1. View

Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre M . The Global Burden of Cancer 2013. JAMA Oncol. 2015; 1(4):505-27. PMC: 4500822. DOI: 10.1001/jamaoncol.2015.0735. View

Fitzmaurice C, Allen C, Barber R, Barregard L, Bhutta Z, Brenner H . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016; 3(4):524-548. PMC: 6103527. DOI: 10.1001/jamaoncol.2016.5688. View

Bray F, Jemal A, Grey N, Ferlay J, Forman D . Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012; 13(8):790-801. DOI: 10.1016/S1470-2045(12)70211-5. View

Brand N, Qu L, Chao A, Ilbawi A . Delays and Barriers to Cancer Care in Low- and Middle-Income Countries: A Systematic Review. Oncologist. 2019; 24(12):e1371-e1380. PMC: 6975966. DOI: 10.1634/theoncologist.2019-0057. View

Romero Y, Trapani D, Johnson S, Tittenbrun Z, Given L, Hohman K . National cancer control plans: a global analysis. Lancet Oncol. 2018; 19(10):e546-e555. DOI: 10.1016/S1470-2045(18)30681-8. View

Mollica M, Falisi A, Geiger A, Jacobsen P, Lunsford N, Pratt-Chapman M . Survivorship objectives in comprehensive cancer control plans: a systematic review. J Cancer Surviv. 2020; 14(2):235-243. PMC: 11057023. DOI: 10.1007/s11764-019-00832-3. View

10.

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M . Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125):1023-1075. PMC: 5879496. DOI: 10.1016/S0140-6736(17)33326-3. View

11.

Hricak H, Abdel-Wahab M, Atun R, Mikhail Lette M, Paez D, Brink J . Medical imaging and nuclear medicine: a Lancet Oncology Commission. Lancet Oncol. 2021; 22(4):e136-e172. PMC: 8444235. DOI: 10.1016/S1470-2045(20)30751-8. View

12.

Martei Y, Iwamoto K, Barr R, Wiernkowski J, Robertson J . Shortages and price variability of essential cytotoxic medicines for treating children with cancers. BMJ Glob Health. 2020; 5(11). PMC: 7656942. DOI: 10.1136/bmjgh-2020-003282. View

13.

Anderson B, Ilbawi A, Fidarova E, Weiderpass E, Stevens L, Abdel-Wahab M . The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases. Lancet Oncol. 2021; 22(5):578-581. DOI: 10.1016/S1470-2045(21)00071-1. View

14.

Lomas A, Leonardi-Bee J, Bath-Hextall F . A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012; 166(5):1069-80. DOI: 10.1111/j.1365-2133.2012.10830.x. View

15.

Sankaranarayanan R . Screening for cancer in low- and middle-income countries. Ann Glob Health. 2014; 80(5):412-7. DOI: 10.1016/j.aogh.2014.09.014. View

16.

Flor L, Reitsma M, Gupta V, Ng M, Gakidou E . The effects of tobacco control policies on global smoking prevalence. Nat Med. 2021; 27(2):239-243. PMC: 7884287. DOI: 10.1038/s41591-020-01210-8. View

17.

Pineros M, Znaor A, Mery L, Bray F . A Global Cancer Surveillance Framework Within Noncommunicable Disease Surveillance: Making the Case for Population-Based Cancer Registries. Epidemiol Rev. 2017; 39(1):161-169. DOI: 10.1093/epirev/mxx003. View

18.

. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1223-1249. PMC: 7566194. DOI: 10.1016/S0140-6736(20)30752-2. View

19.

Sato Y, Fujiwara Y, Fukuda N, Hayama B, Ito Y, Ohno S . Changes in Treatment Behavior during the COVID-19 Pandemic among Patients at a Cancer Hospital. Cancer Cell. 2021; 39(2):130-131. PMC: 7787502. DOI: 10.1016/j.ccell.2021.01.002. View

20.

Oar A, Moraes F, Romero Y, Ilbawi A, Yap M . Core elements of national cancer control plans: a tool to support plan development and review. Lancet Oncol. 2019; 20(11):e645-e652. DOI: 10.1016/S1470-2045(19)30404-8. View